Eli Lilly's GLP-1 Pill Foundayo Shows Efficacy for Sleep Apnea Treatment
New clinical trials indicate Foundayo reduces sleep apnea severity and improves cardiovascular health markers.
1Expanding GLP-1 Therapeutic Scope
Researchers are exploring benefits of GLP-1 medications beyond diabetes and weight management. Eli Lilly’s oral drug Foundayo, known as orforglipron, recently demonstrated success in reducing obstructive sleep apnea episodes. Clinical data suggests these treatments may address obesity-related conditions by targeting hormones, potentially offering patients alternatives to traditional injectable therapies.
2Sleep Apnea Clinical Findings
A study involving over 700 participants across nine countries evaluated Foundayo’s impact on moderate-to-severe sleep apnea. After 52 weeks, patients experienced a significant reduction in breathing interruptions. Specifically, those not using positive airway pressure machines saw a 43.8% decrease in symptom severity, while PAP users saw a 27.5% reduction.
3Weight Loss and Mechanism
Participants in the clinical trial lost an average of 28 pounds, representing approximately 11% of their starting body weight. Weight reduction is a primary factor in alleviating sleep apnea, as excess tissue can restrict airways. Foundayo functions as a daily pill, distinguishing it from existing weekly injectable GLP-1 options.
4Cardiovascular and Inflammatory Impact
Beyond respiratory improvements, Foundayo users showed lower blood pressure and reduced levels of CRP, a key inflammatory marker. Obstructive sleep apnea causes oxygen deprivation, which strains the heart and increases stroke risk. By mitigating these episodes, the drug may provide secondary cardiovascular health benefits for overweight or obese patients.
5Future Regulatory Approval Plans
Eli Lilly intends to submit a formal request to the FDA by the end of 2026 for Foundayo’s approval to treat obstructive sleep apnea. Currently, the drug is approved for chronic weight management. If successful, it would become the third Lilly product indicated for managing this specific sleep-related breathing disorder.
6Retatrutide and Knee Pain
In separate research, the experimental injectable retatrutide showed promise for osteoarthritis in the knee. Targeting three weight-related hormones, the drug helped two-thirds of participants report a 50% reduction in pain. Researchers suggest this relief stems from both reduced joint load and potential anti-inflammatory effects inherent to GLP-1 compounds.
7Metabolic and Physical Relief
Osteoarthritis pain involves complex mechanisms, including physical joint stress and metabolic factors from fat cells. While weight loss directly reduces mechanical pressure on knees, the anti-inflammatory properties of GLP-1 drugs may also play a role. Lilly is currently expanding its research to investigate retatrutide’s efficacy for chronic low back pain.
8Clinical Implications and Outlook
These findings highlight a shift toward using GLP-1 therapies for systemic obesity-related comorbidities. By addressing both respiratory and joint health, these drugs represent a broader approach to metabolic medicine. Future studies will continue to monitor long-term cardiovascular safety and the specific mechanisms driving these diverse therapeutic outcomes in patients.
Original article: Time — Eli Lilly's GLP-1 Pill Foundayo Shows Efficacy for Sleep Apnea Treatment